R+ - MASTOLOGIA
Considere o trecho abaixo retirado da seção StatisticalAnalysis da referência Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 2022;1:EVIDoa2100070; "The trial initially planned to screen approximately 1600 patients and randomly assign 1200 patients to STRIDE, durvalumab, T75+D, and sorafenib (300 per arm). After enrollment closure of the T75+D arm, the protocol was amended to randomly assign 1310 patients: 385 each to STRIDE, durvalumab, and sorafenib as well as 155 to T75+D who were randomly assigned before enrollment closure. (...) Efficacy data were analyzed in the intent-to-treat population, defined as all patients randomly assigned to STRIDE, durvalumab, and sorafenib; no efficacy data are presented for patients in the T75+D arm. Patients were assessed according to the arm to which they were randomly assigned." Baseado nesta leitura, assinale a assertiva CORRETA: